Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) FY26 Q3

Executive Summary

• Burcon Nutrascience reported Q3 2026 revenue of $739,000, a ~107% quarter‑over‑quarter increase and 1,100% year‑over‑year growth driven by the commercial launch of its Galesburg production facility.
• The company now has 200+ active projects in its pipeline, with 65–70% of expected growth coming from existing customers who have already commercialized products.
• Management indicated that staffing and infrastructure are fully in place, allowing incremental volume growth with limited additional fixed costs and supporting operating leverage as throughput rises.

Key Details

• Revenue: $739,000 for Q3 2026 (≈107% QoQ increase).
• Year‑over‑year growth: 1,100% increase versus Q3 2025.
• Production facility: Galesburg site transitioned from development to commercial scale; launched in CY 2025 and met revenue target for the year.
• Customer base: Approximately 65–70% of projected growth tied to repeat purchases from customers who have already commercialized their products.
• Pipeline: Over 200 active projects under development, providing a durable source of recurring revenue.
• Operating leverage: Management expects incremental volume growth with limited additional fixed‑cost investment, enhancing margins as throughput increases.
• Future outlook: Double‑digit revenue growth anticipated for calendar year 2026.

Notable Quotes

(No direct quotes were provided in the release.)